Literature DB >> 21129498

Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs.

Monika Lessl1, Stefanie Schoepe, Anette Sommer, Martin Schneider, Khusru Asadullah.   

Abstract

Collaborations between industry and academia are steadily gaining importance. To combine expertises Bayer Healthcare has set up a novel open innovation approach called Grants4Targets. Ideas on novel drug targets can easily be submitted to http://www.grants4targets.com. After a review process, grants are provided to perform focused experiments to further validate the proposed targets. In addition to financial support specific know-how on target validation and drug discovery is provided. Experienced scientists are nominated as project partners and, depending on the project, tools or specific models are provided. Around 280 applications have been received and 41 projects granted. According to our experience, this type of bridging fund combined with joint efforts provides a valuable tool to foster drug discovery collaborations.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 21129498     DOI: 10.1016/j.drudis.2010.11.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Crowd sourcing in drug discovery.

Authors:  Monika Lessl; Justin S Bryans; Duncan Richards; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 2.  Contributions of academic laboratories to the discovery and development of chemical biology tools.

Authors:  Donna M Huryn; Lynn O Resnick; Peter Wipf
Journal:  J Med Chem       Date:  2013-05-31       Impact factor: 7.446

Review 3.  Opening the door to innovation.

Authors:  Janine Schuurman; Yvo F Graus; Aran F Labrijn; Sigrid Ruuls; Paul W H I Parren
Journal:  MAbs       Date:  2014-04-24       Impact factor: 5.857

4.  Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs.

Authors:  Chiranjib Chakraborty; Bidyut Mallick; Ashish Ranjan Sharma; Garima Sharma; Supriya Jagga; C George Priya Doss; Ju-Suk Nam; Sang-Soo Lee
Journal:  Cell J       Date:  2016-12-21       Impact factor: 2.479

Review 5.  Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

Authors:  Alexander Schuhmacher; Oliver Gassmann; Nigel McCracken; Markus Hinder
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

6.  Development of a High-Throughput Cytometric Screen to Identify Anti- Wolbachia Compounds: The Power of Public-Private Partnership.

Authors:  Rachel H Clare; Roger Clark; Catherine Bardelle; Paul Harper; Matthew Collier; Kelly L Johnston; Helen Plant; Darren Plant; Eileen McCall; Barton E Slatko; Lindsey Cantin; Bo Wu; Louise Ford; David Murray; Kirsty Rich; Mark Wigglesworth; Mark J Taylor; Stephen A Ward
Journal:  SLAS Discov       Date:  2019-04-08       Impact factor: 3.341

Review 7.  Changing R&D models in research-based pharmaceutical companies.

Authors:  Alexander Schuhmacher; Oliver Gassmann; Markus Hinder
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

Review 8.  Crowdsourcing and open innovation in drug discovery: recent contributions and future directions.

Authors:  David C Thompson; Jörg Bentzien
Journal:  Drug Discov Today       Date:  2020-10-02       Impact factor: 7.851

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.